Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:VIRX

Viracta Therapeutics (VIRX) Stock Price, News & Analysis

Viracta Therapeutics logo

About Viracta Therapeutics Stock (NASDAQ:VIRX)

Key Stats

Today's Range
$0.0098
$0.0098
50-Day Range
$0.0096
$0.0178
52-Week Range
$0.01
$0.56
Volume
N/A
Average Volume
1.11 million shs
Market Capitalization
$388.70 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.13
Consensus Rating
Moderate Buy

Company Overview

Viracta Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
22nd Percentile Overall Score

VIRX MarketRank™: 

Viracta Therapeutics scored higher than 22% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Viracta Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Upside Potential

    Viracta Therapeutics has a consensus price target of $1.13, representing about 11,403.1% upside from its current price of $0.01.

  • Amount of Analyst Coverage

    Viracta Therapeutics has received no research coverage in the past 90 days.

  • Read more about Viracta Therapeutics' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Viracta Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Viracta Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Viracta Therapeutics has a P/B Ratio of 0.03. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Viracta Therapeutics' valuation and earnings.
  • Short Interest

    There is no current short interest data available for VIRX.
  • Dividend Yield

    Viracta Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Viracta Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for VIRX.
  • Search Interest

    3 people have searched for VIRX on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Viracta Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    10.69% of the stock of Viracta Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 31.37% of the stock of Viracta Therapeutics is held by institutions.

  • Read more about Viracta Therapeutics' insider trading history.
Receive VIRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viracta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VIRX Stock News Headlines

Why More Investors Are Using Family Trusts to Protect Their Wealth
For many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensuring wealth is passed on according to your wishes. Trusts may also provide shielding from creditors and lawsuits while offering potential tax advantages—especially with estate tax thresholds set to decrease in 2026. If you’re considering whether a family trust is right for you, speaking with a fiduciary financial advisor can help you decide the best path forward. We’ve created a free tool that matches you with vetted advisors in your area—each legally bound to act in your best interest.tc pixel
Viracta Therapeutics terminates employees, to wind down operations
Viracta Therapeutics Announces Wind Down of Operations
See More Headlines

VIRX Stock Analysis - Frequently Asked Questions

Viracta Therapeutics, Inc. (NASDAQ:VIRX) posted its earnings results on Wednesday, November, 10th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by $0.09.

Based on aggregate information from My MarketBeat watchlists, some other companies that Viracta Therapeutics investors own include Meta Platforms (META), Intel (INTC), Applied Genetic Technologies (AGTC), C3.ai (AI), Advanced Micro Devices (AMD) and NVIDIA (NVDA).

Company Calendar

Last Earnings
11/10/2021
Today
9/29/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VIRX
CIK
1061027
Employees
20
Year Founded
2016

Price Target and Rating

High Price Target
$2.00
Low Price Target
$0.25
Potential Upside/Downside
+11,403.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.10)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$51.06 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-1,899.61%
Return on Assets
-114.21%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.76
Quick Ratio
0.76

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.33 per share
Price / Book
0.03

Miscellaneous

Outstanding Shares
39,744,000
Free Float
35,495,000
Market Cap
$388.70 thousand
Optionable
No Data
Beta
1.06

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:VIRX) was last updated on 9/29/2025 by MarketBeat.com Staff
From Our Partners